ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study)

Zhou, Hai-Yu; Zheng, Shao-Peng; Li, An-Lin; Gao, Quan-Long; Ou, Qi-Yun; Chen, Yong-Jian; Wu, Shao-Tao; Lin, Da-Gui; Liu, Sheng-Bo; Huang, Lu-Yu; Li, Fa-Sheng; Zhu, Hong-Yuan; Qiao, Gui-Bin; Lanuti, Michael*; Yao, He-Rui*; Yu, Yun-Fang*广东省人民医院; 广东医学院; 南方医科大学; 汕头大学; 中山大学; 1
ECLINICALMEDICINE2020-7DOI: 10.1016/j.eclinm.2020.100422
17被引5阅读
引用收藏
分享

摘要

Background: The efficacy and safety of neoadjuvant treatment over surgery alone and that of neoadjuvant chemoradiotherapy (NCRT) over neoadjuvant chemotherapy (NCT) in resectable esophageal carcinoma remains inconclusive. This study (NewEC) used global data to comprehensively evaluate these comparisons and to provide a preferable strategy for patient subsets. @@@ Methods: This study included a meta-analysis of randomized controlled trials (RCTs) identified from inception to May 2019 from PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, ClinicalTrials. gov , and congresses and a registry-based cohort study with patients from Massachusetts General Hospital (Massachusetts, USA) and Guangdong Provincial People's Hospital (Guangzhou, China) recruited from November 2000 and June 2017, to cross-validate the comparisons among NCRT versus NCT versus surgery. The GRADE approach was used to assessed quality of evidence in meta-analysis. Neural network machine learning propensity score-matched analysis was used to account for confounding by patient-level characteristics in the cohort study. The primary endpoint was overall survival (OS). The study was registered with PROSPERO CRD42017072242 and ClinicalTrials.gov NCT04027543. @@@ Findings: Of 22,070 studies assessed, there were 38 (n = 6,993 patients) eligible RCTs. Additionally, 423 out of 467 screened patients were included in the cohort study. The results from trials showed that NCT had a better OS than surgery alone (hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.79-0.98; high quality) and was only favorable for adenocarcinoma (HR 0.83, 95% CI 0.72-0.96; moderate quality). High-quality evidence showed a significantly better OS for NCRT than surgery alone (HR 0.74, 95% CI 0.66-0.82) for both adenocarcinoma (HR 0.73, 95% CI 0.62-0.86) and squamous cell carcinoma (SCC) (HR 0.73, 95% CI 0.65-0.83). The OS benefit of NCRT over NCT was seen in the pairwise (HR 0.78, 95% CI 0.62-0.99; high quality) and network (HR 0.82, 95% CI 0.72-0.93; high quality) meta-analyses, with similar results before (HR 0.60, 95% CI 0.40-0.91) and after (HR 0.44, 95% CI 0.25-0.77) matching in the cohort study, leading to a significantly increased 5-year OS rate in both adenocarcinoma and SCC before and after matching. The increased benefits from NCT or NCRT were not associated with the risk of 30-day or in-hospital mortality. @@@ Interpretation: NewEC Study provided high-quality evidence supporting the survival benefits of NCRT or NCT over surgery alone, with NCRT presenting the greatest benefit for resectable esophageal carcinoma.

学科与关键词

关键词
Resectable esophageal carcinomaNeoadjuvant chemotherapyNeoadjuvantChemoradiotherapySurgeryClinical evidence
相关
加载中…
  • Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysis
    Wang, Ting; Cai, Liyu; Guo, Zefeng; You, Peimeng; Liu, Shengbo; Qiu, Hongrui; Li, Hao; Wu, Shaowei; Zhou, HaiyuAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
  • Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
    Pan, Long; Fang, Jing; Tong, Chenhao; Chen, Mingyu; Zhang, Bin; Juengpanich, Sarun; Wang, Yifan*; Cai, Xiujun*WORLD JOURNAL OF SURGICAL ONCOLOGY, BMC, CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, 1, 2020-12-31.被引 4
  • Adjuvant Chemotherapy for Patients with Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Multicenter, Observational Study
    Nie, Run-Cong; Luo, Tian-Qi; Li, Guo-Dong; Zhang, Fei-Yang; Chen, Guo-Ming; Li, Jin-Xing; Chen, Xiao-Jiang; Zhao, Zhou-Kai; Jiang, Kai-Ming; Wei, Yi-Cheng; Huang, Ming-Wei*; Chen, Shi*; Chen, Ying-Bo*Annals of Surgical Oncology, 2022.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
ECLINICALMEDICINE
发表日期
2020-07
卷期
第 24 卷
页码
100422
DOI
10.1016/j.eclinm.2020.100422
成果收录
SCIE
资助标注
National Science and Technology Major Project [2020ZX09201021]; National Natural Science Foundation of China [81572596, 81972471, U1601223]; Natural Science Foundation of Guangdong Province [2017A030313828, 2018A0303130113]; Guangzhou Science and Technology Major Program [201704020131, 201903010028]; Medical artificial intelligence project of Sun Yat Sen Memorial Hospital [YXRGZN201902]; Guangdong Scienceand Technology Department [2017B030314026]; Guangdong Province Medical Scientific Research Foundation [A2015333, B2018148]; Guangdong Provincial People's Hospital Intermural Program [KJ012019447]

作者

  • Z

    Zhou, Hai-Yu (第一作者)

    southern med univ · guangdong prov peoples hosp

  • Z

    Zheng, Shao-Peng

    guangdong prov peoples hosp · southern med univ · shantou univ

查看全部 16 位作者收起作者
  • L

    Li, An-Lin

    1 · sun yat sen univ · guangdong med univ

  • G

    Gao, Quan-Long

    1 · sun yat sen univ · guangdong med univ

  • O

    Ou, Qi-Yun

    1 · sun yat sen univ

  • C

    Chen, Yong-Jian

    sun yat sen univ

  • W

    Wu, Shao-Tao

    guangdong med univ

  • L

    Lin, Da-Gui

    sun yat sen univ

  • L

    Liu, Sheng-Bo

    guangdong prov peoples hosp · southern med univ · guangdong med univ

  • H

    Huang, Lu-Yu

    southern med univ · guangdong prov peoples hosp · shantou univ

  • L

    Li, Fa-Sheng

    southern med univ · guangdong prov peoples hosp

  • Z

    Zhu, Hong-Yuan

    southern med univ · guangdong prov peoples hosp

  • Q

    Qiao, Gui-Bin

    southern med univ · guangdong prov peoples hosp

  • L

    Lanuti, Michael (通讯)

  • Y

    Yao, He-Rui (通讯)

    1 · sun yat sen univ

  • Y

    Yu, Yun-Fang (通讯)

    1 · sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417